Pharmacy
One of the main ways drug spending is mitigated is through market competition from biosimilar and generic drugs.
Competition drives drug prices and results in higher rebates, insurance organization says.
The conspiracy involving secret meetings resulted in higher prices for insurers, the government and consumers, the lawsuit claims.
Investor Carl Icahn says he will vote against $54 billion PBM acquisition as being too high a price.
The merger would increase market concentration in the PBM space and put other insurers at a competitive disadvantage, Dave Jones says.
Announcement comes less than two months after a scathing report from the Office of the Inspector General showing skyrocketing Medicare Part D drug spending.
There may be multiple drugs on the market that have already been shown to be better than the standard, and drugs may even be approved without any comparisons.
Express Scripts is being replaced by in-house pharmacy service; Boost in volume to be mitigated through new fulfillment center and pharmacy robots.
The reports come as GSK also aligned with 23andMe on drug development work.
Communication, technology and referral management will drive success in combating opioid abuse, the Medical Group Management Association says.